Soru

Zorluk: ZorPharmacokinetic and Pharmacodynamic Principles

Match each clinical scenario or physiological state with the most accurate description of its primary pharmacokinetic consequence.

  • Cardiogenic shock with severely diminished cardiac outputDecreased systemic clearance of high-extraction-ratio drugs secondary to diminished organ perfusion
  • Nephrotic syndrome presenting with profound hypoalbuminemiaIncreased active unbound (free) fraction of highly protein-bound acidic drugs
  • Severe sepsis complicated by diffuse capillary leak syndromeExpanded volume of distribution necessitating higher initial loading doses for hydrophilic medications
  • Addition of rifampin to a medication regimen containing a drug with high first-pass hepatic metabolismSubstantially decreased oral bioavailability due to enhanced pre-systemic enzymatic degradation

Cevap

Cardiogenic shock pairs with decreased clearance of high-extraction-ratio drugs; Nephrotic syndrome pairs with increased unbound fraction of acidic drugs; Severe sepsis pairs with expanded volume of distribution for hydrophilic medications; Addition of rifampin pairs with decreased oral bioavailability.
The correct pairings accurately link distinct physiological and clinical states to their primary pharmacokinetic disruptions. Cardiogenic shock causes hypoperfusion, which impairs the flow-dependent clearance of high-extraction-ratio hepatic drugs. Nephrotic syndrome results in hypoalbuminemia, which increases the free fraction of highly protein-bound acidic drugs because there are fewer albumin binding sites. Severe sepsis induces a capillary leak, dramatically expanding the extracellular fluid space and increasing the volume of distribution for hydrophilic drugs, necessitating larger loading doses. Finally, adding a potent CYP inducer like rifampin upregulates intestinal and hepatic enzymes, thereby enhancing first-pass metabolism and markedly reducing the oral bioavailability of susceptible substrates.

Adım Adım Çözüm

1
Analyze the impact of cardiogenic shock on pharmacokinetics.
Recognize that severely decreased cardiac output leads to diminished hepatic blood flow.
Hepatic clearance of high-extraction-ratio drugs is heavily dependent on blood flow (flow-dependent elimination).
2
Evaluate the pharmacokinetic consequence of nephrotic syndrome.
Identify that profound hypoalbuminemia decreases protein binding capacity for acidic drugs.
Fewer albumin binding sites result in an increased active unbound (free) fraction, altering the active drug concentration.
3
Assess the effect of severe sepsis and capillary leak syndrome.
Determine that fluid extravasation significantly expands the extracellular compartment.
This expansion increases the volume of distribution for hydrophilic medications, necessitating higher loading doses to reach target peak levels.
4
Determine the impact of initiating a potent CYP inducer like rifampin.
Conclude that induction of gut and hepatic enzymes increases pre-systemic drug metabolism.
Enhanced first-pass metabolism substantially decreases the oral bioavailability of susceptible substrates.

Anahtar Kavram

Clinical and physiological states directly alter distinct pharmacokinetic parameters such as flow-dependent clearance, protein binding (free fraction), volume of distribution, and pre-systemic extraction.
Bu soruyu puanla